These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 9517926)
1. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Thomas JK; Forrest A; Bhavnani SM; Hyatt JM; Cheng A; Ballow CH; Schentag JJ Antimicrob Agents Chemother; 1998 Mar; 42(3):521-7. PubMed ID: 9517926 [TBL] [Abstract][Full Text] [Related]
2. How can we predict bacterial eradication? Jacobs MR Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703 [TBL] [Abstract][Full Text] [Related]
3. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Bland CM; Pai MP; Lodise TP Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305 [TBL] [Abstract][Full Text] [Related]
4. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Andes D; Anon J; Jacobs MR; Craig WA Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. Gai XY; Bo SN; Shen N; Zhou QT; Yin AY; Lu W Chin Med J (Engl); 2019 Mar; 132(6):638-646. PubMed ID: 30855292 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. Tanigawara Y; Kaku M; Totsuka K; Tsuge H; Saito A J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500 [TBL] [Abstract][Full Text] [Related]
7. Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. Cazzola M; Matera MG; Noschese P Pulm Pharmacol Ther; 2000; 13(6):249-56. PubMed ID: 11061979 [TBL] [Abstract][Full Text] [Related]
8. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Jacobs MR Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855 [TBL] [Abstract][Full Text] [Related]
10. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256 [TBL] [Abstract][Full Text] [Related]
13. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Peric M; Browne FA; Jacobs MR; Appelbaum PC Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. Highet VS; Forrest A; Ballow CH; Schentag JJ J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573 [TBL] [Abstract][Full Text] [Related]
15. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938 [TBL] [Abstract][Full Text] [Related]
16. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Stass H; Dalhoff A Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709 [TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222 [TBL] [Abstract][Full Text] [Related]